SG11201807537RA - Process for the preparation of an antibody-rifamycin conjugate - Google Patents

Process for the preparation of an antibody-rifamycin conjugate

Info

Publication number
SG11201807537RA
SG11201807537RA SG11201807537RA SG11201807537RA SG11201807537RA SG 11201807537R A SG11201807537R A SG 11201807537RA SG 11201807537R A SG11201807537R A SG 11201807537RA SG 11201807537R A SG11201807537R A SG 11201807537RA SG 11201807537R A SG11201807537R A SG 11201807537RA
Authority
SG
Singapore
Prior art keywords
hoffmann
basel
roche
international
dna
Prior art date
Application number
SG11201807537RA
Inventor
Stephan Bachmann
Serena Maria Fantasia
Michael Jansen
Stefan Koenig
Xin Linghu
Sebastian Rieth
Nathaniel L Segraves
Andreas Zogg
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201807537RA publication Critical patent/SG11201807537RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/78—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization IIIM141101110101011111 HO 11111011101111101010 111111111100111110 1111 III N International Bureau ... .jd .... ..or::,„, (10) International Publication Number (43) International Publication Date WO 2017/152083 Al 8 September 2017 (08.09.2017) WIP0 I PCT (51) International Patent Classification: (72) Inventors: BACHMANN, Stephan; c/o F. Hoffmann-La C07D 498/04 (2006.01) CO7C 215/78 (2006.01) Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). FANTASIA, Serena Maria; c/o F. Hoffmann-La Roche (21) International Application Number: AG, Grenzacherstrasse 124, 4070 Basel (CH). JANSEN, PCT/US2017/020711 Michael; c/o F. Hoffmann-La Roche AG, Grenzacher- (22) International Filing Date: strasse 124, 4070 Basel (CH). KOENIG, Stefan; c/o Gen- 3 March 2017 (03.03.2017) entech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). LINGHU, Xin; c/o Genentech, Inc., 1 DNA (25) Filing Language: English Way, South San Francisco, California 94080 (US). RI- (26) Publication Language: English ETH, Sebastian; c/o F. Hoffmann-La Roche AG, Gren- zacherstrasse 124, 4070 Basel (CH). SEGRAVES, Nath- (30) Priority Data: aniel L.; c/o Genentech, Inc., 1 DNA Way, South San 62/303,556 4 March 2016 (04.03.2016) US Francisco, California 94080 (US). ZOGG, Andreas; c/o F. (71) Applicant (for all designated States except AL, AT, BE, Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, Basel (CH). HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, (74) Agents: ANDRUS, Alex et al.; Genentech, Inc., 1 DNA NO, PL, PT, RO, RS, SE, SI, SK, SM, TR): GENENTECH, Way, MS 49, South San Francisco, California 94080 (US). INC. [US/US]; 1 DNA Way, South San Francisco, Califor- nia 94080 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (71) Applicant (for AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, = LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, SM, TR only): F. HOFFMANN-LA ROCHE AG HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, — [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, [Continued on next page] (54) Title: PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE (57) : Processes are described for the preparation of = F-benzoxazinorifamycin I: and intermediates for conjugation with an antibody. — ' = = = Ulf. (.1 .o) — s Batch-reactor . \"I = nah Oxidant 02, I Rmn sv etc benroquinone, RIKA , . n g .1 1-1 0 0— o en GC HO ° Op (;,0,p N 0 0 0 Ho,, HN 0 kr) Il IN Il 0 N O WO 2017/152083 Al MIDEDIMOMOIDEIR0101311101011MMODEVOIMIE MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC , VN, ZA, ZM, ZW. GN, GQ, GW, KM, ML, MR, NE, SN, TD, Published: TG). (84) Designated States (unless otherwise indicated, for every with international search report (Art. 21(3)) kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, — before the expiration of the time limit for claims and to be republished in the event amendments (Rule 48.2(h)) amending of receipt the of
SG11201807537RA 2016-03-04 2017-03-03 Process for the preparation of an antibody-rifamycin conjugate SG11201807537RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662303556P 2016-03-04 2016-03-04
PCT/US2017/020711 WO2017152083A1 (en) 2016-03-04 2017-03-03 Process for the preparation of an antibody-rifamycin conjugate

Publications (1)

Publication Number Publication Date
SG11201807537RA true SG11201807537RA (en) 2018-09-27

Family

ID=58361102

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807537RA SG11201807537RA (en) 2016-03-04 2017-03-03 Process for the preparation of an antibody-rifamycin conjugate

Country Status (13)

Country Link
US (2) US10336683B2 (en)
EP (1) EP3423457B1 (en)
JP (2) JP6705904B2 (en)
KR (1) KR102204805B1 (en)
CN (1) CN108713020A (en)
AR (1) AR107800A1 (en)
AU (1) AU2017228468B2 (en)
BR (1) BR112018014355A2 (en)
CA (1) CA3012046C (en)
IL (1) IL260465B (en)
MX (1) MX2018010491A (en)
SG (1) SG11201807537RA (en)
WO (1) WO2017152083A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107800A1 (en) 2016-03-04 2018-06-06 Genentech Inc PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE
CN108047250B (en) * 2018-02-12 2020-08-14 丹诺医药(苏州）有限公司 Application of rifamycin-nitroimidazole coupled molecule
CN110687217B (en) * 2018-08-07 2021-04-23 中国科学院大连化学物理研究所 Method for measuring rifamycin S by liquid chromatography
CN110687218B (en) * 2018-08-07 2021-04-23 中国科学院大连化学物理研究所 Method for determining benzoxazine rifamycin by liquid chromatography
CN113226470A (en) * 2018-12-21 2021-08-06 瑞泽恩制药公司 Rifamycin analogs and antibody-drug conjugates thereof
WO2023023378A1 (en) * 2021-08-20 2023-02-23 Rutgers, The State University Of New Jersey DUAL-TARGETED RNA POLYMERASE INHIBITORS: CONJUGATES OF BENZOXAZINO- AND SPIRO-RIFAMYCINS WITH Nα-AROYL- N-ARYL-PHENYLALANINAMIDES
CN114436864A (en) * 2022-02-17 2022-05-06 浙江鼎龙科技股份有限公司 Preparation method of 2-methyl-5-aminophenol

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB877732A (en) 1958-08-12 1961-09-20 Lepetit Spa The antibiotic rifomycin, its components and methods of preparing same
US4690919A (en) 1984-01-04 1987-09-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JPS63183587A (en) 1985-02-05 1988-07-28 Kanegafuchi Chem Ind Co Ltd Benzoxazino-rifamycin derivative
CA1304363C (en) 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2004268531A1 (en) 2003-08-22 2005-03-10 Activbiotics, Inc. Rifamycin analogs and uses thereof
EP1725249B1 (en) 2003-11-06 2014-01-08 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
KR20070006698A (en) 2003-12-23 2007-01-11 액티브 바이오틱스 인코포레이티드 Rifamycin analogs and uses thereof
US7265107B2 (en) 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
ES2669510T3 (en) 2004-09-23 2018-05-28 Genentech, Inc. Antibodies and conjugates engineered with cysteine
EP1968600A4 (en) 2005-12-14 2009-07-15 Activbiotics Pharma Llc Rifamycin analogs and uses thereof
US7678791B2 (en) 2006-07-12 2010-03-16 Cumbre Ip Ventures, L.P. Nitroheteroaryl-containing rifamycin derivatives
NZ578851A (en) 2007-03-01 2011-09-30 Symphogen As Method for cloning cognate antibodies
US7723485B2 (en) 2007-05-08 2010-05-25 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
WO2009052249A1 (en) 2007-10-19 2009-04-23 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
US7884099B2 (en) 2007-11-16 2011-02-08 Cumbre Ip Ventures, L.P. Quinolone carboxylic acid-substituted rifamycin derivatives
CN101945848A (en) * 2007-12-20 2011-01-12 英维沃医药有限公司 Tetrasubstituted benzenes
EP2324041A4 (en) 2008-08-13 2012-06-13 Targanta Therapeutics Corp Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2013168965A2 (en) 2012-05-07 2013-11-14 목암생명공학연구소 Vaccine composition for preventing staphylococcus aureus infection
EP2975054A4 (en) 2013-03-12 2016-11-23 Zenyaku Kogyo Kk Anti-staphylococcus antibody, method for manufacturing same, and usage of same
EA201592078A1 (en) * 2013-05-31 2016-04-29 Дженентек, Инк. ANTIBODIES AGAINST TEYHOEIC ACIDS OF THE CELLULAR WALL AND THEIR CONJUGATES
BR112015029754A2 (en) 2013-05-31 2017-09-26 Genentech Inc anti-theoretical wall antibodies and conjugates
TWI632157B (en) * 2013-05-31 2018-08-11 建南德克公司 Anti-wall teichoic acid antibodies and conjugates
RU2017118792A (en) * 2014-12-03 2019-01-09 Дженентек, Инк. ANTIBODY CONJUGATES TO STAPHYLOCOCCUS AUREUS WITH RIFAMICINE AND THEIR APPLICATION
MX2017007055A (en) * 2014-12-03 2017-11-08 Genentech Inc Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof.
AR107800A1 (en) 2016-03-04 2018-06-06 Genentech Inc PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE

Also Published As

Publication number Publication date
CA3012046C (en) 2020-11-10
KR20180118173A (en) 2018-10-30
JP2019510740A (en) 2019-04-18
WO2017152083A1 (en) 2017-09-08
KR102204805B1 (en) 2021-01-20
AU2017228468B2 (en) 2019-12-05
BR112018014355A2 (en) 2018-12-18
EP3423457B1 (en) 2021-02-17
US20190270695A1 (en) 2019-09-05
AR107800A1 (en) 2018-06-06
US10336683B2 (en) 2019-07-02
JP6705904B2 (en) 2020-06-03
AU2017228468A1 (en) 2018-07-26
US20170252457A1 (en) 2017-09-07
CN108713020A (en) 2018-10-26
IL260465B (en) 2020-11-30
EP3423457A1 (en) 2019-01-09
JP2020090506A (en) 2020-06-11
MX2018010491A (en) 2018-11-09
US10689325B2 (en) 2020-06-23
CA3012046A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
SG11201807537RA (en) Process for the preparation of an antibody-rifamycin conjugate
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811432WA (en) Rna for cancer therapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201807187XA (en) Binding members to pd-l1
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201901531TA (en) Regulation of gene expression using engineered nucleases
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201909011PA (en) Niraparib compositions
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201810525XA (en) Anti-gitr antibodies and uses thereof